Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital

被引:32
作者
Keating, Karen [1 ]
Walko, Christine [1 ]
Stephenson, Briana [2 ]
O'Neil, Bert H. [3 ]
Weiss, Jared [4 ]
机构
[1] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA
[3] Indiana Univ, Simon Ctr, Indianapolis, IN 46204 USA
[4] Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC 27599 USA
关键词
anaphylaxis; Cetuximab; Erbitux; hypersensitivity reactions; oncology;
D O I
10.1177/1078155213510542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The primary purpose of this study was to determine the rate of infusion reactions to cetuximab in oncology patients treated at the University of North Carolina Cancer Hospital. Secondarily, we sought to evaluate predictors of grade 3-4 hypersensitivity, including geography. Methods Data were collected by retrospective chart review for patients treated with cetuximab at the University of North Carolina Cancer Hospital between 15 November 2006 and 31 December 2010. Data were analyzed for occurrence of hypersensitivity reaction in 125 patients with various cancer types. Results Of the 125 subjects, 31 (24.8%) experienced an infusion reaction of any grade. Of 125, 18 (14.4%) experienced a grade 3 or 4 reaction. The odds ratio for patients with an allergy history having a grade 3 or 4 reaction was 2.57 (95% CI 0.93 to 7.09, p=0.07). Pretreatment with steroids was associated with absence of grade 3 or 4 reaction with an odds ratio of 0.21 (95% CI 0.05 to 0.83, p=0.04). Mapping of reaction rates by county revealed higher rates in some of the more rural counties of North Carolina, however, statistical power was lacking. Conclusions Rates of hypersensitivity reaction at UNC are similar to rates seen in other areas of the southeastern United States and higher than in other regions of the United States and Europe. Rates of both hypersensitivity reactions and grade 3 to 4 hypersensitivity reactions have not substantially changed over time. Geography, allergy history, and perhaps smoking or cancer type may help predict who will react to cetuximab. Steroids should be strongly considered as premedication in addition to diphenhydramine.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 26 条
[1]  
Blick S.K., Scott L.J., Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer, Drugs, 67, pp. 2585-2607, (2007)
[2]  
Erbitux (Package Insert), (2013)
[3]  
Cunningham D., Humblet Y., Siena S., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, pp. 337-345, (2004)
[4]  
Bonner J.A., Harari P.M., Giralt J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 354, pp. 567-578, (2006)
[5]  
Bonomi P.D., Mace J., Mandanas R.A., Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with Stage IIIB/IV non-small-cell lung cancer, J Thorac Oncol, 8, pp. 338-345, (2013)
[6]  
Carey L.A., Rugo H.S., Marcom P.K., TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer, J Clin Oncol, 30, pp. 2615-2623, (2012)
[7]  
Asnacios A., Fartoux L., Romano O., Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: Results of a multicenter phase 2 study, Cancer, 112, pp. 2733-2739, (2008)
[8]  
Foley K.A., Wang P.F., Barber B.L., Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab, Ann Oncol, 21, pp. 1455-1461, (2010)
[9]  
Siena S., Glynne-Jones R., Adenis A., Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication, Cancer, 116, pp. 1827-1837, (2010)
[10]  
Sobrero A.F., Maurel J., Fehrenbacher L., EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, pp. 2311-2319, (2008)